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INTRODUCTION: The evaluation of endothelial function has been performed in the arterial bed, but recently evaluation within 
the venous system has also been explored. Endothelial function studies employ different drugs that act as endothelium-dependent 
vasodilatory response inductors. 
OBJECTIVES: The aim of this study is to compare the endothelium-dependent venous vasodilator response mediated by either 
acetylcholine or bradykinin in healthy volunteers.
METHODS AND RESULTS: Changes in vein diameter after phenylephrine-induced venoconstriction were measured to compare 
venodilation induced by acetylcholine or bradykinin (linear variable differential transformer dorsal hand vein technique). We studied 
23 healthy volunteers; 31% were male, and the subject had a mean age of 33 ± 8 years and a mean body mass index of 23 ± 2 kg/
m2. The maximum endothelium-dependent venodilation was similar for both drugs (p = 0.13), as well as the mean responses for 
each dose of both drugs (r = 0.96). The maximum responses to acetylcholine and bradykinin also had good agreement.
CONCLUSION: There were no differences between acetylcholine and bradykinin as venodilators in this endothelial venous 
function investigation. 
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INTRODUCTION
Evaluation of endothelial function has been investigated 
in recent years using different approaches, and these 
results have contributed significantly to the understanding 
of its importance in physiological and pathological 
conditions.1-3 Endothelial dysfunction is frequently present 
in common chronic degenerative disorders, such as diabetes, 
hypertension and coronary artery disease.4 Thus, its detection 
may assist in the prevention and early treatment of these 
diseases.
Although traditionally the evaluation of endothelial 
function has been performed in the arterial bed, recently 
the evaluation of the venous system has been explored 
under diverse conditions.5-7 The venous system contains ~ 
70% of the blood volume, which is mainly present in small 
veins.8 Arteries and veins have different biological activities 
in terms of the endothelium; this is most likely due to 
marked regional and segmental heterogeneity in vascular 
endothelial function.6 Veins are extremely important under 
specific conditions, such as hypertension, heart failure, and 
other cardiovascular disorders.5,7-9 Studies on arterial and 
venous endothelial function usually employ drugs that act 
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as inductors of the endothelium-dependent vasodilatory 
response.10 The endothelium-dependent vasodilatory 
response may be elicited by infusion of substances that 
promote the synthesis or liberation of nitric oxide (NO) 
by the endothelium. Bradykinin, for example, is produced 
from its substrate, kininogen, by the action of kallikrein. 
Endothelial cells express, in a constitutive manner, B2 
kinin receptors, which are activated by, among other 
substances, bradykinin. Agonism of these receptors activates 
phospholipase c, mobilizing the entrance of intracellular 
calcium, which stimulates NO synthesis. Thus, the end 
effect of the bradykinin action is to enhance endothelium-
dependent vasodilatation through the liberation of NO.11 As 
bradykinin effects are predominantly local in the evaluation 
of the venous endothelium, several studies have utilized 
the infusion of this substance to induce an endothelium-
dependent response.6,12,13 
Because of the way in which the vasomotor response to 
acetylcholine or other agonists of the muscarinic receptors 
are evaluated, several studies have also utilized regional 
infusions of this substance, usually intra-arterial, to measure 
endothelium-dependent vasodilation.2,14,15 The use of 
acetylcholine in this context has potential advantages: the 
simplicity of its use, its favorable cost and its well-known 
effects on the arterial endothelium. However, studies 
performed in the late 1980s that utilized acetylcholine as an 
endothelium-dependent vasodilator agent demonstrated that 
high-dose infusions of acetylcholine caused a vasoconstrictor 
effect in the venous endothelium.9,16 One of these studies 
demonstrated that only low-dose acetylcholine infusions 
produced vasodilation.16 
Faced with these findings, in this study we intend to 
perform, in healthy volunteers, a comparative analysis of 
the endothelium-dependent venous vasodilator response 
mediated by acetylcholine vs. bradykinin.
METHODS
Subjects
The study was carried out in 23 healthy volunteers, 
31% male, with a mean age of 33 ± 8 years (range 20 to 
45) and a mean body mass index of 23 ± 2 kg/m2. All were 
healthy, as determined by a complete physical examination 
and routine laboratory tests (fasting glycemia, lipids, full 
blood count). Exclusion criteria were a personal history of 
diabetes, hypertension, and any vascular disease, drug abuse, 
alcoholism, smoking or chronic use of any medication. Each 
subject gave written informed consent to participate in this 
study, which was approved by the ethical committee of our 
institution. 
Dorsal Hand Vein Technique
The dorsal hand vein technique, previously modified 
by Aellig,17 was used to measure the responsiveness of 
the dorsal hand vein to acetylcholine, bradykinin and 
sodium nitroprusside in the hand vein pre-constricted using 
phenylephrine. In each experimental session, we allowed 
a 20 min interval between infusions of both acetylcholine 
and sodium nitroprusside, and bradykinin and sodium 
nitroprusside. The subjects were studied in the supine 
position with one arm placed on a padded support with an 
upward angle of 30 degrees from the horizontal position to 
ensure complete emptying of the superficial hand veins. A 
suitable vein was chosen on the dorsum of the hand, and 
a 23-gauge needle was inserted. A tripod holding a linear 
variable differential transformer (Shaevitz Engineering, 
NJ) was mounted on the back of the hand, with the central 
aperture of the linear variable differential transformer, 
containing a movable metal core, at a distance of 10 mm 
downstream from the tip of the needle. The signal output 
of the linear variable differential transformer, which is 
linearly proportional to the vertical of the core, gives a 
measurement of the diameter of the vein. Readings were 
made under a congestive pressure of 40 mmHg by inflating 
a blood pressure cuff placed on the upper portion of the 
arm under study. Normal saline solution was infused for at 
least 30 min to allow for equilibration of the veins after the 
initial vasoconstriction due to needle insertion. This baseline 
vasodilation during saline infusion with the cuff inflated was 
defined as 100% relaxation; the recording obtained with the 
cuff not inflated (and the vein emptied) was defined as 100% 
constriction. The difference between the two positions of 
the core gave a measure of the diameter changes of the vein 
under congestive pressure. All local drug infusions lasted for 
at least 3 min. At the end of this time, the cuff was inflated 
up to the maximum response or by a 3-min period, even 
if no response was obtained. Subsequently, the cuff was 
deflated. Increasing concentrations of a drug were infused 
in a sequential manner. 
Phenylephrine, an α-adrenoceptor-selective agonist, was 
used to produce vasoconstriction of the hand vein. A dose-
response curve to phenylephrine was performed in each 
subject with a dose range of 0.06 to 8 nmol/min. In this way, 
the dose of phenylephrine that produced 80% of maximal 
venous constriction was determined and was kept constant 
during the entire study, and this degree of constriction was 
defined as 0% dilatation for the purpose of subsequent 
calculations. We allowed a 20-min interval between 
infusions of agonists. Since acetylcholine and bradykinin 
are rapidly degraded and each dose was only injected after 
complete recovery (approximately 2 min) of venous tone to 
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baseline, baseline conditions were re-established between 
the drug injections and between the different agonists. 
Preliminary experiments indicated that phenylephrine-
induced venoconstriction was stable during this period.18 
The vasodilator response in this study was calculated as 
a percentage in the range of 0 to 100% dilation. Drugs were 
infused using a Harvard infusion pump (Harvard Apparatus, 
South Natick, MA) at a flow rate of 0.3 ml/min. Blood 
pressure and heart rate were monitored in the opposite arm 
during the experiment. All experiments were performed in a 
temperature-controlled laboratory (26-28ºC).
Endothelium-dependent venodilation was tested by 
infusing five increasing doses (0.02-20 nmol/min) of 
acetylcholine (Sao Paulo University, Pharmacy Division, Sao 
Paulo, Brazil) and five increasing doses (1-260 pmol/min) of 
bradykinin (Clinalfa). Endothelium-independent venodilation 
was tested by infusing three increasing doses (2–7 nmol/min) 
of sodium nitroprusside (Biolab Sanus Pharmacy Ltda, Sao 
Paulo, Brazil).
Data analysis
The variables are reported as mean ± standard deviation. 
Comparisons between continuous variables were performed 
using the Student t-test or Wilcoxon test for nonparametric 
values, and those between categorical variables were 
made using the χ2 test for trend. The relationship between 
endothelial function and clinical variables was evaluated by 
calculating the Pearson correlation coefficient. Values of p 
< 0.05 were considered to be statistically significant. This 
analysis was performed with the statistics software SAS 6.0 
for Windows.
RESULTS
Clinical characteristics of the studied subjects were as 
follows: the subjects were on average 33 years-old, 31% 
were male, they had normal weight and body mass index, 
and they also had normal blood pressure levels and plasma 
lipids and glucose, as expected (Table 1).
Acetylcholine, bradykinin, phenylephrine and sodium 
nitroprusside infusions were well tolerated. None of the 
pharmacological intervention procedures resulted in 
changes in the blood pressure or heart rate, indicating that 
the doses used had no systemic effect, as expected. The 
maximum endothelium-dependent venodilation responses 
obtained by administering acetylcholine or bradykinin 
were that acetylcholine elicited an endothelium-dependent 
venodilation of 88 ± 38%, while bradykinin causes a 105 ± 
41% venodilation (p = 0.12), as compared to basal values 
(Figure 1).
The numerical values for acetylcholine and bradykinin 
responses, at each dose tested, are represented in Figure 
2 and are also given at the bottom of the figure. The 
mean venodilation induced by 0.02 to 20 nmol/min of 
acetylcholine and 1 to 260 pmol/min of bradykinin were 
similar. The data suggest a similar initial behavior of 
dose-dependent vasodilation, with dependent and linear 
characteristics for both infusions.
We also performed a correlation by plotting the 
percentage vasodilation observed with each dose of 
acetylcholine vs. the percentage vasodilation observed with 
Table 1 - Characteristics of the studied subjects
Characteristic Mean ± SD or n (%)
Age (years) 33 ± 8
Gender (male) 7 (30%)
Race (Caucasian) 23 (100%)
Weight (kg) 65 ± 9
Height (m) 1.69 ± 0.08
BMI (Kg/m2) 22.8 ± 2.3
SBP (mmHg) 113 ± 13
DBP (mmHg) 73 ± 7
PP (mmHg) 38 ± 8
HR (bpm) 72 ± 7
Glycemia (mg/dL) 87 ± 8
Total cholesterol (mg/dL) 190 ± 37
Triglycerides (mg/dL) 91 ± 46
HDL-c (mg/dL) 63 ± 14
Hematocrit (%) 40 ± 3
The values are reported as mean ± standard deviation or percentages. 
BMI: Body mass index; SBP: Systolic blood pressure; DBP: diastolic 
blood pressure; PP: Pulse pressure; HR: Heart rate; HDL-c: High-density 
lipoprotein cholesterol.
Figure 1 - Percentage maximal response from baseline (maximal effect, %) 
after infusion of acetylcholine (ACH) and bradykinin (BK)
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each dose of bradykinin; there was good agreement between 
the responses for each drug (r = 0.96, p = 0.007).
DISCUSSION
The most important finding of the present study was the 
demonstration that acetylcholine, administered in low-to-
moderate concentrations, may be used as a tool to analyze 
endothelium-dependent venodilation using the dorsal 
hand vein technique. This finding is based on the direct 
comparison of data obtained with bradykinin in the same 
subjects.
The first study19 involving venous endothelium reported 
a dose-dependent dilator effect of acetylcholine on pre-
constricted superficial hand veins, an effect that could be 
blocked by the local infusion of atropine. Removal of the 
endothelium of the vein by local irrigation with distilled 
water abolished the acetylcholine venodilator effect, which 
could therefore be ascribed to the effect of locally-released 
NO.20 Studies carried out by Vallance et al. also showed that 
the venodilation produced by acetylcholine is mediated via 
endothelium NO release.9 However, in veins with an intact 
endothelium, the dose-response relationship for acetylcholine 
was found to be biphasic; low doses produce venodilation, 
and high doses produce venoconstriction. In light of these 
results, other authors questioned the use of this drug in 
dose-response curves as an endothelial function evaluation.16 
Bradykinin has been used to evaluate endothelium-dependent 
venodilation because of the possibility of constructing a 
dose-effect curve. 5,6,12,21
In the present study, we compared the endothelium-
dependent venodilation response produced by acetylcholine 
and bradykinin in healthy individuals. We observed that 
the maximum mean responses produced by acetylcholine 
and bradykinin were similar in healthy individuals. In 
their classic study, Collier et al. showed that the maximum 
response produced by acetylcholine was 28% at a dose of 1 
nmol/min; 10 nmol/min did not produce venodilation and 
100 nmol/min produced venoconstriction.16 Furthermore, 
the authors demonstrated that the venodilation was 
endothelium-dependent, since the response was abolished 
after endothelium removal. In the present study, we evaluated 
the dorsal hand vein response in 23 healthy individuals, and 
the doses of acetylcholine were 0.02 to 20 nmol/min (5 
doses). The maximum venodilatory response was 88 ± 38%, 
as compared to the 5 doses of bradykinin usually employed 
that caused a maximum response of 105 ± 41%. The 
difference between the two substances was mainly due to the 
concentration of the acetylcholine doses. It is important to 
note that we did not find evidence of desensitization during 
acetylcholine dose-response curves.
Many hypotheses have been proposed to explain the 
variability of maximum venodilation during acetylcholine-
infusion, which may be derived from the functional 
endothelium or the vascular smooth muscle.22 Indeed, 
the use of this technique has been well accepted in the 
literature, but some variability is expected, as demonstrated 
by previous studies.22,23 Concerning other factors that might 
contribute to the heterogeneous venodilatory responses 
to acetylcholine, Grossmann et al. tested if the variable 
responses to acetylcholine in healthy subjects could be 
associated with two polymorphisms for proteins involved in 
the signal transduction pathway (the G-protein beta-3 subunit
 
GNB3) and endothelial nitric oxide synthase, (eNOS). They 
concluded that the variable venous responses to acetylcholine 
in humans were not related to acetylcholine esterase activity, 
GNB3 or the eNOS gene variant.23 Finally, tachyphilaxis, a 
process characterized by a gradual reduction in the number 
of receptors or a change in their conformation, inhibiting 
the adequate link between the agonist under its continued 
exposition to the receptor, could not be excluded. However, 
this mechanism was not explored in the present study.
Similar responses to acetylcholine and bradykinin at 
different doses were observed upon comparison. However, 
the pattern of venodilation produced by bradykinin was 
similar to that of acetylcholine, which might be explained 
by the multiple mechanisms involved in this process; 
the stimulation of the B2 receptors causes liberation of 
prostacyclin, NO and a hyperpolarizing factor derived from 
the endothelium.24 It is believed that vasodilation mediated 
by acetylcholine occurs only via NO.20
The performance of acetylcholine as compared to 
bradykinin in inducing endothelium venous vasodilatory 
was evaluated considering several aspects. The relationship 
between venodilation response for each dose of infused 
acetylcholine and bradykinin showed that the drugs had 
Figure 2 - Relationship between venodilation responses (% mean venodila-
tion) for each dose of acetylcholine (ACH) or bradykinin (BK) infusion
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equivalent actions, implying that they are both efficient 
in venous endothelium evaluation. There is evidence in 
humans that both drugs have a similar vasomotor response 
pattern in coronary arteries,25 which reinforces the idea that 
the utilization of acetylcholine as a vasodilatory stimulus is 
comparable to bradykinin in the venous endothelium. 
In conclusion, there were no differences between 
acetylcholine and bradykinin as they were used as 
venodilators in this endothelial venous function investigation. 
Both drugs may be safely used for the evaluation of 
endothelial venous function. This fact is very important, 
since acethylcholine is cheaper than bradykinin.
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